Polygala tenuifolia for Health & Longevity

Evidence Review created on 10/18/2026 using AI4L + evidence-mcp / Gemini 4 Argon

Also known as: Yuan Zhi, Yuanzhi, Radix Polygalae, Polygalae Radix, Thinleaf Milkwort, Chinese Senega, Onji, BT-11, PDC-1421

Motivation

Polygala tenuifolia (commonly known as Yuan Zhi, Thinleaf Milkwort, or Radix Polygalae) is a perennial herb native to East Asia whose dried root has been used for over two millennia in traditional Chinese, Korean, and Japanese medicine. In contemporary health and longevity circles, standardized oral root extracts—including the Korean formulation BT-11 and the experimental herbal extract PDC-1421—attract interest for supporting memory, attention, mood stability, and long-term brain resilience.

Active plant compounds concentrated in the root bark interact with brain chemical messengers involved in memory and mood, cellular waste-clearing pathways, and inflammatory responses. While traditional texts paired processed Polygala tenuifolia root with complementary herbs to support aging cognition and calm emotional distress, modern researchers have evaluated isolated single-herb extracts in controlled human trials investigating verbal recall, working memory, and depressive symptoms.

This review examines the human trial and laboratory evidence for Polygala tenuifolia across cognitive performance, mood regulation, and cellular aging, alongside its digestive and metabolic safety profile, drug and supplement interactions, traditional root processing requirements, and practical dosing protocols.

Benefits - Risks - Protocol - Conclusion

The following primary clinical study and comprehensive narrative reviews provide an overview of Polygala tenuifolia phytochemistry, neuropharmacology, clinical evaluation, and safety.

Note: Direct searches of the prioritized longevity platforms—Rhonda Patrick (FoundMyFitness), Peter Attia, Andrew Huberman (Huberman Lab), Chris Kresser, Life Extension Magazine, and Lifespan.io—yielded no dedicated articles, podcasts, or commentary on Polygala tenuifolia (Yuan Zhi), as its clinical research remains concentrated in East Asian phytopharmacology and specialized neuropsychiatry journals.

Grokipedia

No Grokipedia article exists for Polygala tenuifolia (or Yuan Zhi / Radix Polygalae) as of October 2026.

Examine

Polygala tenuifolia

This dedicated monograph summarizes traditional Chinese medicine uses of Yuan Zhi, bioactive xanthones and saponins, human trials of the standardized root extract BT-11 (100 mg three times daily) for memory, and safety considerations.

ConsumerLab

No ConsumerLab product review or article exists for Polygala tenuifolia (or Yuan Zhi / Radix Polygalae) as of October 2026.

Systematic Reviews

The following systematic reviews and meta-analyses evaluate Polygala tenuifolia extracts and traditional herbal combinations for cognitive performance, neurodegenerative disorders, and clinical safety.

While Zhang et al., 2023 and Liu et al., 2024 meta-analyze clinical adverse event rates alongside cognitive efficacy, no standalone systematic review or meta-analysis exclusively evaluating Polygala tenuifolia toxicity or drug interactions exists on PubMed.

Mechanism of Action

Polygala tenuifolia root provides triterpenoid saponins (onjisaponin B and sapogenins tenuifolin and senegenin), oligosaccharide esters (3,6’-disinapoyl sucrose [DISS]), and xanthones (polygalaxanthone III) (Zhao et al., 2020). Competing hypotheses explain its central activity. The cholinergic-neurotrophic model attributes memory effects to non-competitive inhibition of acetylcholinesterase (AChE, an enzyme degrading the neurotransmitter acetylcholine) by BT-11 (commercialized by affiliate Braintropia, a financial conflict of interest; Park et al., 2002) and upregulation of brain-derived neurotrophic factor (BDNF, a synaptic growth protein) (Jiang et al., 2021). A competing monoaminergic model centers on yuanzhi-1, a saponin inhibiting serotonin, norepinephrine, and dopamine transporters (SERT, NET, and DAT, proteins clearing synaptic monoamines) (Jin et al., 2014). Extracts also activate adenosine monophosphate-activated protein kinase (AMPK, a cellular energy sensor) and inhibit mechanistic target of rapamycin (mTOR, a nutrient-sensing growth regulator) to stimulate neuronal autophagy (cellular waste clearance) (Zhao et al., 2015).

Parent saponins show low rodent oral bioavailability (0.83%–8.7%) as gut microbiota and esterases hydrolyze them into metabolites (sinapic acid, tenuifolin, and senegenin) that cross the blood-brain barrier within 5–12 minutes, distribute to brain, liver, kidney, heart, and spleen, and clear with 1.5–4.7-hour half-lives (Ma et al., 2014; Shen et al., 2022; Zhang et al., 2022). Constituents selectively inhibit hepatic cytochrome P450 (CYP, liver drug-metabolizing enzymes) isoform CYP2E1 without inhibiting CYP1A2, CYP2A6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, or CYP3A4 (Li et al., 2014), while inhibiting intestinal P-glycoprotein (P-gp, a drug efflux pump) (Ba et al., 2019) and organic anion-transporting polypeptide 2B1 (OATP2B1, an uptake transporter) (Iijima et al., 2018).

Historical Context & Evolution

Recorded over two millennia ago in the Shennong Bencao Jing (c. 1st–2nd century CE) as a “top-grade” herb suitable for long-term use, Polygala tenuifolia (Yuan Zhi) was traditionally prescribed to “calm the heart, quiet the spirit, expel phlegm, and sharpen memory” (Zhao et al., 2020). A systematic analysis of 127 classical Chinese medical texts spanning c. 188–1920 CE ranked Polygala tenuifolia among the top three herbs across 731 prescriptions for memory disorders, notably in the Tang-dynasty formula Kai-Xin-San (May et al., 2013). Classical physicians also observed that raw root irritated the throat and stomach, establishing licorice-simmered (Zhi Yuanzhi) and honey-baked processing standards that remain in East Asian pharmacopoeias (Cui et al., 2021).

Interest shifted toward modern cognitive optimization in the 2000s when Seoul National University researchers developed BT-11 (commercialized via affiliate Braintropia, a financial conflict of interest), an ethanolic root extract that reversed scopolamine-induced amnesia in rats (Park et al., 2002) and improved immediate verbal recall and global cognition in two 2009 placebo-controlled human trials (Lee et al., 2009; Shin et al., 2009). Subsequent discovery of the triple monoamine reuptake inhibitor yuanzhi-1 (Jin et al., 2014) prompted manufacturer BioLite (a financial conflict of interest) to sponsor clinical trials of extract PDC-1421 for major depressive disorder (NCT02395978) and adult attention-deficit/hyperactivity disorder (ADHD, a neurodevelopmental attention condition) (NCT05202327). While BT-11 cognitive trials reported statistically significant gains, Phase II trials of PDC-1421 did not demonstrate superiority over placebo, leaving single-herb clinical efficacy under active investigation.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High because randomized controlled trials of single-herb Polygala tenuifolia demonstrating significant clinical improvements originate from a single research group, while trials from other independent groups either tested multi-herb combinations or showed non-significant differences against placebo.

Medium 🟩 🟩

Memory and Cognitive Function in Healthy Adults

Oral BT-11 (300 mg/day) improves global cognition in older adults (Shin et al., 2009) and immediate verbal recall in younger adults (Lee et al., 2009) via AChE inhibition and neurotrophic support. Evidence comes from two RCTs (N=53 and N=48) by one group affiliated with developer Braintropia (a financial conflict of interest). However, recognition and working memory in Lee et al., 2009 improved only within-group, and in a 27-RCT network meta-analysis (Wang et al., 2025) Polygala tenuifolia improved global cognition without outperforming placebo on memory or executive function.

Magnitude: Improved global cognition vs. placebo by a standardized mean difference (SMD, effect size in standard deviation units) of 1.28 (95% confidence interval [CI, range of plausible true values]: 0.69 to 1.88; surface under the cumulative ranking curve [SUCRA, a 0–100% probability ranking of treatment efficacy]: 95.9%, ranked first across 27 RCTs), while overall memory (SMD = 0.18, 95% CI: -0.49 to 0.85) and executive function (SMD = -0.26, 95% CI: -0.80 to 0.28) did not differ significantly from placebo (Wang et al., 2025); in individual trials, BT-11 significantly outperformed placebo on Consortium to Establish a Registry for Alzheimer’s Disease (CERAD, a standardized cognitive assessment battery) total score (Shin et al., 2009) and Korean California Verbal Learning Test (K-CVLT, a verbal memory test) immediate recall (Lee et al., 2009).

Low 🟩

Cognitive and Daily Function Support in Mild Cognitive Impairment and Alzheimer’s Disease

Formulas containing Polygala tenuifolia improve cognition in mild cognitive impairment (MCI, an intermediate cognitive decline stage) (Liu et al., 2024) and Alzheimer’s disease (AD, a neurodegenerative dementia) (Zhang et al., 2023; Watari et al., 2019). Evidence is indirect because all trials co-administered herbs like Acorus tatarinowii or Kihito.

Magnitude: Across 16 AD RCTs (Zhang et al., 2023), adding Polygala tenuifolia plus Acorus tatarinowii to conventional AD drugs (10 RCTs) improved Mini-Mental State Examination (MMSE, a 30-point cognitive test) by a mean difference (MD, average difference between groups) of 2.57 points (95% CI: 1.44 to 3.69) and reduced Alzheimer’s Disease Assessment Scale-Cognitive Subscale (ADAS-cog, an impairment scale where lower scores are better) by MD -2.09 points (95% CI: -3.07 to -1.10) vs. conventional drugs alone (while 6 RCTs of the herb pair alone matched conventional drugs); across 13 MCI RCTs (Liu et al., 2024), formulas improved MMSE by MD 1.90 points (95% CI: 1.22 to 2.58; 11 RCTs, N=823) and Montreal Cognitive Assessment (MoCA, a 30-point cognitive screen) by MD 2.88 points (95% CI: 1.69 to 4.06; 3 RCTs, N=241) vs. placebo.

Depressive Symptom Reduction ⚠️ Conflicted

Yuanzhi-1 inhibits SERT, NET, and DAT to elevate synaptic monoamines (Jin et al., 2014). In a 6-week Phase II RCT (N=60) sponsored by manufacturer BioLite (a financial conflict of interest), oral PDC-1421 numerically lowered depression scores without reaching statistical significance over placebo (NCT02395978). Net reading: antidepressant efficacy remains unproven.

Magnitude: In the 6-week Phase II RCT (NCT02395978), Montgomery-Åsberg Depression Rating Scale (MADRS, a 0–60 clinician-rated depression scale) total scores changed within each group by -13.19 ± 9.68 points with high-dose PDC-1421 (2,280 mg/day, n=21) and -9.21 ± 8.32 points with low-dose PDC-1421 (1,140 mg/day, n=19) vs. -9.20 ± 7.98 points with placebo (n=20) (not compared between groups as pairwise differences; overall three-group Kruskal-Wallis probability value p = 0.393, where p < 0.05 indicates statistical significance; 95% CI not reported).

Attention and Executive Function in Attention-Deficit/Hyperactivity Disorder ⚠️ Conflicted

Saponin NET and DAT inhibition targets attention pathways (Jin et al., 2014). Although an open-label BioLite study (N=6) reported improvement (NCT02699086), an 8-week quadruple-blind RCT (N=69) found lower response rates with PDC-1421 than placebo (NCT05202327). Net reading: controlled trial data show no benefit over placebo.

Magnitude: In the 8-week quadruple-blind RCT (NCT05202327), ≥40% improvement on the Attention-Deficit/Hyperactivity Disorder Rating Scale-IV (ADHD-RS-IV, an 18-item symptom scale) occurred in 9/23 (39.1%) low-dose (1,140 mg/day) and 10/24 (41.7%) high-dose (2,280 mg/day) PDC-1421 participants and 11/22 (50.0%) placebo participants, with within-group ADHD-RS-IV total score changes of -13.61 ± 10.02, -11.75 ± 10.20, and -12.14 ± 10.56 points, respectively (not compared between groups), whereas the uncontrolled open-label study (NCT02699086) reported 5/6 (83.3%) responders (no control group).

Speculative 🟨

Lifespan Extension and Systemic Stress Resistance

Extracts extended Caenorhabditis elegans (roundworm) lifespan and reduced mouse aging via complement C3 (an immune protein) and mitogen-activated protein kinase (MAPK, a stress-signaling enzyme) (Zeng et al., 2021; Zhang et al., 2025). Evidence is preclinical.

Neuronal Autophagy Induction and Ferroptosis Inhibition

Extracts induce AMPK/mTOR autophagy (Zhao et al., 2015). An injected multi-herb formula activates antioxidant signaling to block mouse ferroptosis (iron-driven cell death) (Qian et al., 2026). Evidence is preclinical and indirect (multi-herb, injected).

Benefit-Modifying Factors

  • Genetic polymorphisms: Variants in ABCB1 (P-gp efflux pump gene) or SLCO2B1 (OATP2B1 uptake transporter gene) may alter intestinal ester and xanthone absorption (Ba et al., 2019; Iijima et al., 2018), while APOE4 (apolipoprotein E4, an Alzheimer’s risk gene) may modify cognitive response.
  • Baseline cognitive and biomarker status: Cognitive gains in RCTs spanned multiple CERAD subtests in older adults with lower baseline scores (Shin et al., 2009), whereas high-performing younger adults showed between-group gains only in K-CVLT immediate recall (Lee et al., 2009).
  • Sex-based differences: Human RCTs of BT-11 (Shin et al., 2009; Lee et al., 2009) and PDC-1421 (NCT02395978, NCT05202327) enrolled both men and women without reporting sex-stratified efficacy differences, leaving sex-specific pharmacodynamic variations unestablished.
  • Pre-existing health conditions and gut dysbiosis: Because parent saponins and oligosaccharide esters require intestinal esterases and gut microbiota for conversion into brain-penetrant metabolites (Shen et al., 2022; Zhang et al., 2022), intestinal dysbiosis (microbial imbalance) or recent antibiotic exposure may blunt systemic bioactivity.
  • Age-related considerations: Older adults aged 60–80 years demonstrated broader cognitive domain improvements across naming, praxis, and constructional recall (Shin et al., 2009), consistent with age-related declines in basal central cholinergic tone that AChE-inhibiting extracts help compensate.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High because across randomized placebo-controlled trials and meta-analyses from independent research groups, standardized Polygala tenuifolia extracts have not produced any statistically significant excess of serious or treatment-limiting adverse events compared to placebo.

Medium 🟥 🟥

No risk reaches Medium because mild adverse events reported in single-sponsor Phase I and II clinical trials of PDC-1421 did not reach statistical significance over placebo and conflict with randomized placebo-controlled trials of BT-11 and meta-analyses showing no excess adverse event risk.

Low 🟥

Gastrointestinal Irritation, Dyspepsia, and Dry Mouth ⚠️ Conflicted

Saponins irritate gastric mucosa (Cui et al., 2021). PDC-1421 trials noted mild dry mouth and dyspepsia (indigestion) (NCT02395978, NCT05202327), whereas a BT-11 RCT (Park et al., 2019) and meta-analyses (Zhang et al., 2023; Liu et al., 2024) found no excess risk. Net reading: processed post-meal extracts rarely cause distress.

Magnitude: Overall adverse event relative risk (RR, ratio of event probabilities between groups) was 0.65 (95% CI: 0.35 to 1.19) for Polygala tenuifolia plus Acorus tatarinowii added to conventional AD drugs vs. conventional drugs alone in 10 AD RCTs (Zhang et al., 2023) and 1.31 (95% CI: 0.92 to 1.87) vs. placebo across 11 MCI RCTs (N=839; Liu et al., 2024); in NCT02395978, dry mouth occurred in 3/21 (14.3%) high-dose and 3/19 (15.8%) low-dose PDC-1421 participants vs. 1/20 (5.0%) on placebo, and epigastric (upper stomach) discomfort in 2/21 (9.5%) vs. 0/20 (0%) on placebo.

Mild Dizziness, Lethargy, and Tachycardia ⚠️ Conflicted

Monoamine modulation may provoke dizziness, lethargy, or tachycardia (heart rate >100 beats/min). Small numerical increases occurred with high-dose PDC-1421 (NCT02395978, NCT05202327), whereas a 12-week BT-11 RCT (N=121) found no vital sign differences vs. placebo (Park et al., 2019). Net reading: autonomic side effects are rare at standard doses.

Magnitude: In NCT02395978, dizziness occurred in 2/21 (9.5%) high-dose and 0/19 (0%) low-dose PDC-1421 participants vs. 0/20 (0%) on placebo; in NCT05202327, lethargy, headache, and tachycardia each occurred in 2/24 (8.3%) high-dose and 0/23 (0%) low-dose participants vs. 0/22 (0%) on placebo; in Park et al., 2019, total adverse events were 10/61 (16.4%) with BT-11 vs. 6/60 (10.0%) with placebo (not statistically significant).

Transient Liver Transaminase Elevation ⚠️ Conflicted

Metabolites undergo hepatic clearance (Ma et al., 2014). One high-dose PDC-1421 participant had reversible alanine aminotransferase (ALT, a liver enzyme) and aspartate aminotransferase (AST, a hepatic enzyme) elevation (NCT02395978), whereas BT-11 (Park et al., 2019) and Phase I (NCT01774045) trials found zero hepatic abnormalities. Net reading: hepatotoxicity is rare.

Magnitude: Elevated ALT and AST occurred in 1/21 (4.8%) high-dose PDC-1421 participants and 0/19 (0%) low-dose participants vs. 0/20 (0%) on placebo in NCT02395978, and in 0/61 (0%) BT-11 participants vs. 0/60 (0%) on placebo over 12 weeks in Park et al., 2019.

Speculative 🟨

Raw Root Saponin Mucosal Toxicity and Gastric Hypomotility

Raw saponins lower gastric prostaglandin E2 (a protective lipid), deplete Cajal gastric pacemaker cells, and cause rodent hypomotility (slowed stomach emptying) (Yang et al., 2011; Cui et al., 2021). Evidence is preclinical.

Drug Transporter and Cytochrome P450 2E1 Inhibition

Extracts inhibit human OATP2B1 (>80% at 100 µg/mL) (Iijima et al., 2018), hepatic CYP2E1 (Li et al., 2014), and rat intestinal P-gp (Ba et al., 2019). Evidence comes from in-vitro and rodent assays.

Risk-Modifying Factors

  • Genetic polymorphisms: Variants in SLCO2B1 (OATP2B1) or ABCB1 (P-gp) may amplify transporter-mediated interactions with co-administered medications (Iijima et al., 2018; Ba et al., 2019), while CYP2E1 variants could alter clearance of co-ingested CYP2E1 substrates (Li et al., 2014).
  • Baseline biomarker levels: Elevated baseline ALT or AST, or a prolonged corrected QT interval (QTc, a heart electrical recovery measure >450 ms per NCT05202327), increases susceptibility to hepatic transaminase elevations or cardiac conduction disturbances.
  • Sex-based differences: Clinical safety trials of BT-11 (Park et al., 2019) and PDC-1421 (NCT01774045, NCT02395978) reported no sex-based differences in overall adverse event rates, although 1/21 high-dose participants in NCT02395978 reported irregular menstruation.
  • Pre-existing health conditions: History of gastritis, peptic ulcer disease, or gastroesophageal reflux heightens sensitivity to saponin-induced mucosal irritation (Zhao et al., 2020; Cui et al., 2021), while baseline tachycardia or anxiety may worsen with high-dose monoaminergic extracts (NCT05202327).
  • Age-related considerations: Older adults tolerated 300 mg/day of BT-11 without moderate or severe adverse events (Shin et al., 2009), but age-related polypharmacy increases exposure to OATP2B1 and P-gp transporter drug interactions (Iijima et al., 2018).

Key Interactions & Contraindications

  • OATP2B1 substrate prescription medications (fexofenadine, rosuvastatin, fluvastatin, aliskiren): Caution (theoretical); boiling-water Polygala tenuifolia extract inhibited human OATP2B1 uptake by >80% in vitro (Iijima et al., 2018), potentially reducing intestinal absorption and efficacy of co-administered substrates. Spacing oral doses by 2–3 hours mitigates this competition.
  • P-glycoprotein substrate prescription medications (digoxin, dabigatran, cyclosporine, loperamide): Monitor (theoretical); Polygala tenuifolia total saponins inhibited intestinal P-gp efflux in rat gut sacs (Ba et al., 2019), potentially increasing systemic drug absorption. Dosing separation by 2–3 hours and drug-level monitoring mitigate this risk.
  • Monoaminergic antidepressants and stimulants (fluoxetine, venlafaxine, methylphenidate, selegiline): Caution (theoretical); yuanzhi-1 inhibits SERT, NET, and DAT (Jin et al., 2014), and clinical trials required a 2-week antidepressant washout (4 weeks for fluoxetine; NCT02395978) due to potential additive tachycardia, anxiety, or serotonergic overstimulation.
  • Prescription acetylcholinesterase inhibitors (donepezil, rivastigmine, galantamine): Monitor (theoretical); Polygala tenuifolia inhibits AChE (Park et al., 2002). Adding Kihito to cholinesterase inhibitors in 10 AD patients caused no serious adverse events (Watari et al., 2019), though nausea or bradycardia (slow heart rate) can occur.
  • Tamoxifen: Contraindicated in oncology trials (protocol exclusion); the Phase I/II trial of PDC-1421 in cancer patients explicitly excludes concurrent tamoxifen therapy (NCT03833206) to prevent potential botanical-drug interference with endocrine treatment.
  • Major cytochrome P450 (CYP1A2, CYP2A6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A4) substrates (warfarin, midazolam, metoprolol, omeprazole): No interaction observed in vitro; five bioactive Polygala tenuifolia constituents showed no inhibition of these seven human liver microsomal enzymes (Li et al., 2014).
  • Over-the-counter CYP2E1 substrates and mucolytics (mucus-thinning agents; acetaminophen, ethanol, chlorzoxazone, ambroxol): Caution for CYP2E1 substrates (theoretical); five constituents inhibited human CYP2E1 in vitro (Li et al., 2014), whereas rat co-administration did not alter ambroxol pharmacokinetics (Yang et al., 2021). Heavy alcohol use may slow clearance.
  • Over-the-counter nonsteroidal anti-inflammatory drugs (ibuprofen, naproxen, aspirin): Caution (theoretical); raw Polygala tenuifolia saponins reduce gastric prostaglandin E2 in rodents (Yang et al., 2011), which may compound nonsteroidal anti-inflammatory drug mucosal irritation and dyspepsia. Post-meal administration of processed extracts reduces mucosal irritation.
  • Cholinergic and monoaminergic supplements (huperzine A, citicoline, Bacopa monnieri, Rhodiola rosea, St. John’s wort): Caution (theoretical); combining Polygala tenuifolia with AChE-inhibiting or monoamine-active supplements (Park et al., 2002; Jin et al., 2014) may cause cramping, headache, or insomnia. Gradual single-agent introduction helps isolate intolerances.
  • Fasting or empty-stomach administration: Caution; ingesting concentrated saponin extracts during fasting increases direct gastric mucosal irritation (Cui et al., 2021). Clinical trials mandate post-meal administration (NCT01774045, NCT02395978) to minimize abdominal fullness.

Populations who should avoid Polygala tenuifolia:

  • Active peptic ulcer disease, erosive gastritis, or clinically significant gastrointestinal disorders: Excluded in human clinical trials (NCT01774045, NCT02395978) and contraindicated in traditional pharmacopoeias because triterpenoid saponins irritate gastric mucosa and suppress prostaglandin E2 (Zhao et al., 2020; Yang et al., 2011).
  • Cardiac conduction abnormalities (QTc > 450 ms) or uncontrolled cardiovascular disease: Adult clinical trials excluded individuals with Fridericia-corrected QTc intervals >450 ms or unstable cardiovascular disease (NCT02699086, NCT05202327), and mild tachycardia occurred in 2/24 high-dose participants (NCT05202327).
  • Clinically significant hepatic or renal dysfunction, or severe anemia (hemoglobin < 10 g/dL): Clinical protocols excluded participants with abnormal baseline hepatic or renal laboratory values (NCT01774045, NCT02395978) or hemoglobin <10 g/dL (NCT03833206).
  • History of epilepsy, seizure disorders, bipolar disorder, or psychosis: Excluded across Phase II trials (NCT02395978, NCT05202327, NCT03833206) due to central monoamine reuptake inhibition.
  • Pregnancy and lactation: All controlled trials required negative pregnancy tests and contraception through 15 days post-treatment (NCT01774045, NCT02395978, NCT05202327).

Risk Mitigation Strategies

Doses, timing separations, and monitoring intervals below reflect common practice unless cited.

  • Use licorice- or honey-processed extracts (Zhi Yuanzhi) or standardized extracts: Selecting processed root or standardized extracts (like BT-11) hydrolyzes harsh saponin glycosyl chains, mitigating throat irritation, gastric mucosal injury, and hypomotility (Wen et al., 2015; Cui et al., 2021).
  • Administer strictly after meals: Taking oral capsules within 15–30 minutes after meals—the exact regimen used in Phase I and II trials (NCT01774045, NCT02395978)—buffers mucosa-irritating saponins and reduces epigastric discomfort, dyspepsia, and abdominal fullness.
  • Begin at low cognitive doses rather than high psychiatric doses: Starting at 100 mg three times daily (300 mg/day, as in Lee et al., 2009) rather than 1,140–2,280 mg/day (NCT02395978) minimizes dry mouth, dizziness, lethargy, and tachycardia.
  • Separate dosing from OATP2B1 and P-gp substrate medications: Spacing Polygala tenuifolia intake by 2–3 hours from oral statins (cholesterol-lowering drugs), antihistamines (allergy medications), or P-gp substrates mitigates intestinal transporter competition (Iijima et al., 2018; Ba et al., 2019).
  • Monitor liver enzymes and pause if elevated: Checking ALT and AST at baseline and after 4–6 weeks of high-dose use (NCT02395978), and discontinuing supplementation if transaminases exceed the normal reference range, prevents progressive hepatic injury.

Therapeutic Protocol

Timing, titration steps, and administration details without a citation below reflect common practice.

  • Standardized cognitive extract regimen (BT-11 approach): 100 mg administered orally three times daily (300 mg/day) of ethanolic root extract, developed at Seoul National University (Lee et al., 2009; Shin et al., 2009; Park et al., 2019).
  • High-dose botanical extract regimen (PDC-1421 approach): 380 mg to 760 mg (1–2 capsules) administered orally three times daily after meals (1,140–2,280 mg/day total), evaluated in BioLite Phase II depression and attention trials (NCT02395978, NCT05202327).
  • Traditional decoction and multi-herb granules: 3–10 g/day of licorice-processed dried root (Zhi Yuanzhi) in decoctions (Zhao et al., 2020; 6–9 g twice daily in NCT07768579), or 2.5 g three times daily of Kampo Kihito granules (Watari et al., 2019).
  • Pharmacokinetic half-life and split dosing: Because active metabolites (tenuifolin, senegenin, and phenolic acids) have short elimination half-lives of 1.5–4.7 hours in vivo (Ma et al., 2014; Shen et al., 2022), protocols use three-times-daily split dosing rather than once-daily dosing.
  • Time of day and meal timing: Doses are taken immediately after breakfast, lunch, and dinner (NCT01774045, NCT02395978); individuals experiencing mild evening alertness from monoamine reuptake inhibition take the final dose with a late-afternoon meal.
  • Genetic polymorphisms: No clinical pharmacogenomic dosing guidelines exist, but carriers of reduced-function SLCO2B1 or ABCB1 alleles or CYP2E1 variants may experience altered intestinal transport or hepatic clearance (Iijima et al., 2018; Li et al., 2014).
  • Age and sex considerations: Identical 300 mg/day BT-11 regimens (100 mg three times daily) are used across youths (Park et al., 2019), younger adults (Lee et al., 2009), older adults (Shin et al., 2009), and both sexes without adjustment.
  • Baseline biomarkers and pre-existing conditions: Normal baseline ALT/AST and QTc ≤450 ms are verified before high-dose regimens (NCT02395978, NCT05202327), while gastric sensitivity warrants strict post-meal administration of processed extracts (Cui et al., 2021).

Discontinuation & Cycling

  • Treatment duration (short-term vs. lifelong use): Controlled single-herb trials evaluated continuous use for 4–12 weeks (Lee et al., 2009; Park et al., 2019) and multi-herb formulas for 16–52 weeks (Watari et al., 2019; NCT07768579); lifelong safety data are absent.
  • Withdrawal effects: No rebound cognitive decline or physical withdrawal syndrome was reported during 1-week post-treatment follow-up in PDC-1421 trials (NCT02395978, NCT02699086), though cognitive scores returned toward baseline within 16 weeks after stopping Kihito (Watari et al., 2019).
  • Tapering protocol: Standard cognitive doses (100 mg three times daily) can be stopped abruptly without tapering, whereas high-dose regimens (1,140–2,280 mg/day) are commonly stepped down by 50% for 1 week to avoid transient monoaminergic mood fluctuations.
  • Cycling protocols: While clinical trials used continuous daily dosing for 4–12 weeks (Lee et al., 2009; Park et al., 2019), nootropic practitioners commonly apply 8-to-12-week cycles followed by a 2-to-4-week washout or 5-days-on, 2-days-off schedules to limit transporter adaptation.

Sourcing and Quality

  • Botanical species authentication: While the Korean Pharmacopoeia restricts Polygalae Radix to Polygala tenuifolia, the Chinese Pharmacopoeia permits Polygala tenuifolia Willd. and Polygala sibirica L., and commercial roots risk confusion with Polygala japonica (Jeong et al., 2025). Genetic or chromatographic testing confirms species identity.
  • Pharmacopoeial chemical markers and standardization: The Chinese Pharmacopoeia specifies minimum marker contents of ≥0.15% polygalaxanthone III, ≥0.50% 3,6’-disinapoyl sucrose (DISS), and ≥2.0% tenuifolin (Zhao et al., 2020; Xu et al., 2017). Quality-assured extracts standardize to these three reference markers.
  • Root bark vs. woody core and processing status: Bioactive saponins concentrate in the root bark rather than the inert woody core (removed during preparation), and licorice-simmered (Zhi Yuanzhi) or honey-processed preparations reduce mucosal irritation (Zhao et al., 2020; Cui et al., 2021).
  • Formulations and reputable suppliers: Standardized 20:1 hydroethanolic root extracts (such as Nootropics Depot Polygala tenuifolia), Korean BT-11 functional foods (Park et al., 2019), and Good Manufacturing Practice (GMP, a pharmaceutical quality standard) Kampo granules (Tsumura Kihito; Watari et al., 2019) offer batch-tested purity.
  • Third-party contaminant testing: Because root crops bioaccumulate soil heavy metals (lead, cadmium, arsenic, mercury), mycotoxins, and agricultural pesticides (Zhao et al., 2020), accredited third-party laboratory Certificates of Analysis (formal batch quality testing reports) verify contaminant-free batches.

Practical Considerations

  • Time to effect: Oral DISS peaks in rat plasma within 12 minutes and reduces mouse anxiety acutely (Zhang et al., 2022), whereas human immediate verbal recall and CERAD cognitive gains required 4–8 weeks in RCTs (Lee et al., 2009; Shin et al., 2009).
  • Common pitfalls: Taking unbuffered raw root or extracts on an empty stomach (causing throat irritation and dyspepsia; Cui et al., 2021), taking a single daily dose instead of three split doses, and confusing botanical BT-11 with the unrelated synthetic drug omilancor (also coded BT-11).
  • Regulatory status: Listed in the Chinese and Korean Pharmacopoeias (Zhao et al., 2020; Jeong et al., 2025) and approved as a Korean functional food ingredient (BT-11; Park et al., 2019), it is sold as a United States dietary supplement while PDC-1421 remains investigational (NCT02395978).
  • Cost and accessibility: Standardized 20:1 Polygala tenuifolia extracts and traditional Zhi Yuanzhi granules are inexpensive ($15–$30 for a 1- to 2-month supply at 300 mg/day) and widely accessible online, whereas proprietary prescription-grade PDC-1421 capsules are restricted to clinical trials.

Interaction with Foundational Habits

  • Sleep: Potentiating at standard doses, blunting at high late doses (direct); tenuifolin and senegenin promote rodent sleep via gamma-aminobutyric acid (GABA, primary inhibitory neurotransmitter) (Jiang et al., 2021) and Panax ginseng-paired extracts activate melatonin pathways (Xia et al., 2024), whereas high-dose PDC-1421 caused insomnia in 1/12 Part I participants (NCT02395978). Daytime dosing avoids alertness.
  • Nutrition: Potentiating (direct gastrointestinal buffering and microbiome biotransformation); post-meal administration buffers mucosa-irritating saponins against gastric irritation (NCT01774045), while dietary prebiotic fiber supports the intestinal microbiota required to hydrolyze parent saponins and DISS into brain-penetrant tenuifolin and senegenin (Shen et al., 2022). No micronutrient depletions are documented.
  • Exercise: Potentiating (indirect mechanistic synergy); no human trial has combined Polygala tenuifolia with exercise, but aerobic training and Polygala extracts independently upregulate hippocampal BDNF signaling and AMPK-mediated neuronal autophagy (Jiang et al., 2021; Zhao et al., 2015). Pre-workout high doses may compound exercise-induced heart rate elevations (NCT05202327).
  • Stress management: Potentiating (direct neuroendocrine modulation); oligosaccharide esters and polygalasaponins attenuate chronic stress-induced hypothalamic-pituitary-adrenal (HPA, the central neuroendocrine stress response system) axis hyperactivation, lower corticosterone, and preserve hippocampal neurogenesis in rodent stress models (Jiang et al., 2021; Zhao et al., 2020).

Monitoring Protocol & Defining Success

Before initiating oral Polygala tenuifolia supplementation, baseline testing establishes hepatic enzyme safety (ALT and AST), resting cardiac rhythm stability (seated resting heart rate), and objective cognitive or mood reference scores prior to botanical exposure (NCT01774045, NCT02395978). Ongoing clinical monitoring follows a structured cadence at 1 week for early resting heart rate and gastrointestinal tolerance, at 4 weeks and 8–12 weeks for repeat hepatic panels and standardized cognitive or mood re-testing, and every 6 months during extended supplementation to verify sustained efficacy and biochemical safety (Lee et al., 2009; Shin et al., 2009; Park et al., 2019). Alongside laboratory and scale metrics, qualitative markers define day-to-day response:

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Alanine aminotransferase (ALT) & Aspartate aminotransferase (AST) ALT: 7–56 U/L; AST: 8–33 U/L (standard reference range) Safety check: detects transient hepatic transaminase elevation that requires pausing or stopping use. U/L (units per liter). Draw fasting in the morning at baseline, 4–6 weeks, and every 6 months; pair with total bilirubin and alkaline phosphatase (NCT01774045, NCT02395978).
Resting Heart Rate 60–100 beats/min (standard reference range) Safety check: identifies monoaminergic tachycardia (>100 beats/min) or palpitations that prompt dose reduction or discontinuation. Measure seated after 5 minutes of morning rest at baseline, 1 week, and 4 weeks; pair with a 12-lead electrocardiogram if QTc >450 ms is suspected (NCT05202327).
Validated Cognitive Battery (CERAD, MoCA, or K-CVLT) No established target; track improvement from the individual’s own baseline score Efficacy marker: quantifies expected changes in global cognition, word list recognition, constructional recall, and immediate verbal recall. Administer at a consistent morning timepoint in a rested state at baseline, 4 weeks, and 8–12 weeks (Shin et al., 2009; Lee et al., 2009).
Validated Mood or Attention Scale (MADRS or ADHD-RS-IV) No established target; track score reduction from the individual’s own baseline Efficacy marker: evaluates symptom trajectory when used for mood or executive attention support. Assess at baseline, 4 weeks, and 6–8 weeks at the same time of day (NCT02395978, NCT05202327).
  • Cognitive clarity: Word retrieval, name recall, and sustained task focus.
  • Gastrointestinal tolerance: Post-meal epigastric fullness, dry mouth, or dyspepsia.
  • Sleep and energy: Sleep onset latency, nighttime awakenings, and daytime alertness.

Emerging Research

  • PDC-1421 Phase I/II trial for depression in cancer patients (NCT03833206): Not-yet-recruiting open-label dose-escalation trial (N=12, Stage I–III cancer, 1,140–2,280 mg/day for 28 days, primary endpoint 5-week MADRS change, estimated completion February 2028). A positive result would support safety and mood-lifting potential in oncology patients; a null result or toxicity would weaken clinical antidepressant claims.
  • Prospective sequential therapy cohort in Alzheimer’s disease (NCT07768579): Recruiting 12-month multicenter cohort (N=600, ages 55–85, completion December 2028) evaluating stage-adapted formulas with processed Polygala tenuifolia (6–9 g twice daily) on Clinical Dementia Rating-Sum of Boxes (CDR-SB, a 0–18 dementia scale) and ADAS-cog. Positive findings would strengthen multi-herb neuroprotection; null findings would weaken disease-modifying claims.
  • Completed Phase II RCTs of PDC-1421 in depression (NCT02395978) and adult ADHD (NCT02699086, NCT05202327): Completed with posted results (NCT01774045 confirmed Phase I safety up to 3,800 mg). Despite 5/6 open-label ADHD responders (NCT02699086), randomized depression outcomes were non-significant (p = 0.393) and ADHD responder rates (39.1%–41.7%) trailed placebo (50.0%), weakening monotherapy psychiatric claims.
  • Neuronal ferroptosis and bioenergetic restoration: Preclinical studies show that a Polygala tenuifolia-containing formula inhibits neuronal ferroptosis and tau pathology in amyloid-beta-induced AD model mice (Qian et al., 2026) and Polygalae Radix extracts restore brain energy metabolism in Parkinson’s disease models (Jiao et al., 2026). Future human biomarker trials could validate or refute these neuroprotective pathways.
  • Human pharmacokinetic and transporter interaction trials: Because gut microbiota biotransformation (Shen et al., 2022) and OATP2B1, P-gp, and CYP2E1 inhibition (Iijima et al., 2018; Ba et al., 2019; Li et al., 2014) remain characterized only in rodents and in-vitro assays, clinical drug-interaction studies could either confirm safe co-administration or reveal limiting drug interactions.

Conclusion

Polygala tenuifolia root is a traditional East Asian herbal intervention whose active root bark compounds slow the breakdown of memory-related brain chemicals, support mood-regulating chemical messengers, promote brain cell growth signals, and stimulate cellular waste clearance. For proactive adults pursuing cognitive longevity, the strongest human evidence supports improvements in overall cognitive performance in older adults and immediate verbal recall in younger adults with standardized oral root extracts, whereas broader memory and mental planning measures did not outperform placebo in pooled analyses. Multi-herb formulas pairing Polygala tenuifolia with complementary herbs also show supportive evidence for preserving cognition and daily function in age-related cognitive decline, while isolated extract trials for depression and attention disorders have not outperformed placebo.

The overall evidence base remains preliminary and carries structural limitations. Positive single-herb cognitive trials originate from a single academic research group affiliated with the commercial developer of the tested extract, while independent clinical trials of a competing herbal extract were funded by its pharmaceutical sponsor—financial conflicts of interest that temper confidence in the magnitude of reported benefits. Across controlled human studies, processed extracts administered orally after meals are generally well tolerated, with mild dry mouth, stomach fullness, indigestion, dizziness, and rare, reversible liver blood marker elevations representing the primary adverse events. Selecting licorice-processed or standardized root bark extracts, splitting doses across meals, and spacing intake away from oral medications that rely on gut absorption and transport proteins address the main practical considerations.

Top - Benefits - Risks - Protocol